Open AccessCHANGES IN SERUM LIPIDS DURING TREATMENT WITH NORGESTREL, OESTRADIOL‐VALERATE AND CYCLOPROGYNON®
Author(s) -
Nielsen F. Hassing,
Honoré E.,
Kristoffersen K.,
Secher N. J.,
Pedersen G. Thomsen
Publication year - 1977
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.3109/00016347709154994
Subject(s) - estradiol valerate , valerate , norgestrel , endocrinology , medicine , levonorgestrel , triglyceride , cholesterol , climacteric , population , estrogen , menopause , chemistry , biochemistry , research methodology , environmental health , family planning , fermentation , butyrate
. The serum concentrations of triglycerides, cholesterol, and free glycerol were determined in 23 climacteric women, before and after the administration of three different steroid drugs. Each drug was given within a period of 12 weeks (3 cycles). Period I: Norgestrel, 0.5 mg daily from the 12th to 21st day of each cycle. Period II: Oestradiol‐valerate (Progynon®) 2 mg daily from the 2nd to 21st day of each cycle. Period III: Oestradiol‐valerate 2 mg from the 1st to 11th day followed by oestradiol‐valerate 2 mg+0.5 mg dl ‐norgestrel from day 12 to 21 of each cycle (Cycloprogynon®). A significant decrease in triglycerides was observed following the administration of norgestrel and Cycloprogynon®, whereas oestradiol‐valerate had no effect on the triglyceride levels. On the other hand, oestradiol‐valerate, following a period of norgestrel, produced an increase in serum cholesterol levels.